New therapies and old side‐effects in mycosis fungoides treatment: brentuximab vedotin‐induced alopecia

Abstract

Brentuximab Vedotin (BV, SNG35) is an antibody drug‐conjugated against CD30 molecule. It consists of a chimeric monoclonal anti CD30 antibody, which by binding CD30 extracellular domains, allows a chemotherapeutic agent, monomethyl auristatin E (MME) to penetrate neoplastic cells. This causes apoptosis of the neoplastic cells, by arresting the cell cycle in G2/M phase¹. Recent clinical trials have shown BV's efficacy in CD30 positive mycosis fungoides (MF) with an objective global response of 56·3%^1,2,3.

This article is protected by copyright. All rights reserved.

https://ift.tt/2Bt5dcl